Skip to content

The Tuberculosis Vaccines Pipeline

  • Chad Cipiti

July 2014 Back to basic science By Mike Frick The last year in tuberculosis (TB) vaccine research has demonstrated how setbacks can sometimes produce the potential for unexpected progress. Dominant hypotheses have yielded to new investigative directions, and unresolved questions…

Read more

Playing Catch-Up: The Pediatric Tuberculosis Treatment Pipeline

  • Chad Cipiti

July 2014 By Lindsay McKenna Introduction While the pediatric HIV drug pipeline has seen increased activity in recent years, the same cannot be said for pediatric TB. Adult-pediatric approval gaps remain an issue in HIV drug development, especially for children…

Read more

Tuberculosis Drug Development Hobbles Forward

  • Chad Cipiti

July 2014 By Erica Lessem Introduction After forty years without new approved drug classes, tuberculosis (TB) treatment has recently advanced with the approval of two new compounds to treat multidrug-resistant TB (MDR-TB): delamanid and bedaquiline.1,2,3 Yet with limited access to…

Read more

The Tuberculosis Diagnostics Pipeline

  • Chad Cipiti

July 2014 By Colleen Daniels Accurate diagnosis of tuberculosis (TB) is the gateway to treatment and—it is hoped—cure for people with latent TB infection (LTBI) or active TB disease. According to the Stop TB Partnership and the World Health Organization…

Read more

Global Update: Hepatitis C Treatment Activism

  • Chad Cipiti

By Karyn Kaplan and Tracy Swan How can governments and donors effectively address HCV if pharma refuses to drop drug prices?   —Paata Sabelashvili, Activist, Georgian Harm Reduction Network Keeping up with the rapid pace of hepatitis C drug development,…

Read more

2013/2014 HCV Drug Pipeline Update

  • Chad Cipiti

July 2014 By Tracy Swan Thanks to Jules Levin This update includes presentations from the American Association for the Study of Liver Diseases (AASLD) Meeting, the Conference on Retroviruses and Opportunistic Infections (CROI), the European Association for the Study of…

Read more

The Pediatric Antiretroviral Pipeline

  • Chad Cipiti

July 2014 By Polly Clayden Since last year’s Pipeline Report, dolutegravir (DTG) was approved for children aged 12 years and older in the United States and Europe.1,2 The approvals for this age group were granted at the same time as…

Read more

Fit for Purpose: Treatment Optimization

  • Chad Cipiti

July 2014 By Polly Clayden Since the 2013 Pipeline Report treatment optimization has continued to gain traction. Results from one of the key dose optimization trials ENCORE1—showing a lower dose of efavirenz (EFV) is non-inferior to the currently approved one—…

Read more

Research Toward a Cure and Immune-Based and Gene Therapies

  • Chad Cipiti

Update July 18, 2014 Disappointing news regarding the "Mississippi baby" case described in this chapter was announced on July 10th by the National Institute of Allergy and Infectious Diseases (NIAID). Viral load rebounded to detectable levels, dashing hopes that a…

Read more
Back To Top